In the past week, SPRY stock has gone down by -8.78%, with a monthly gain of 3.29% and a quarterly plunge of -31.75%. The volatility ratio for the week is 7.20%, and the volatility levels for the last 30 days are 7.31% for ARS Pharmaceuticals Inc The simple moving average for the last 20 days is -10.52% for SPRY stock, with a simple moving average of -2.86% for the last 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
SPRY has 36-month beta value of 1.00. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for SPRY is 50.50M, and currently, short sellers hold a 29.05% ratio of that float. The average trading volume of SPRY on February 13, 2025 was 1.31M shares.
SPRY) stock’s latest price update
The stock of ARS Pharmaceuticals Inc (NASDAQ: SPRY) has increased by 0.69 when compared to last closing price of 11.55. Despite this, the company has experienced a -8.78% fall in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-06 that ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy’s early sales also beat expectations, which I think showcases how much of a blockbuster it could become over time. Neffy targets several segments within severe allergic reactions and could also become an OTC medication soon. In total, this is a multibillion-dollar TAM.
Analysts’ Opinion of SPRY
Many brokerage firms have already submitted their reports for SPRY stocks, with Oppenheimer repeating the rating for SPRY by listing it as a “Outperform.” The predicted price for SPRY in the upcoming period, according to Oppenheimer is $40 based on the research report published on February 10, 2025 of the current year 2025.
Raymond James gave a rating of “Strong Buy” to SPRY, setting the target price at $22 in the report published on August 13th of the previous year.
SPRY Trading at -6.11% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.17% of loss for the given period.
Volatility was left at 7.31%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares surge +2.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.96% lower at present.
During the last 5 trading sessions, SPRY fell by -8.78%, which changed the moving average for the period of 200-days by +43.76% in comparison to the 20-day moving average, which settled at $13.00. In addition, ARS Pharmaceuticals Inc saw 10.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from Shawver Laura, who sale 50,000 shares at the price of $12.31 back on Feb 03 ’25. After this action, Shawver Laura now owns 210,346 shares of ARS Pharmaceuticals Inc, valued at $615,565 using the latest closing price.
Shawver Laura, the Director of ARS Pharmaceuticals Inc, proposed sale 50,000 shares at $12.31 during a trade that took place back on Feb 03 ’25, which means that Shawver Laura is holding shares at $615,565 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -23.84 for the present operating margin
- 0.94 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -19.35. The total capital return value is set at -0.3. Equity return is now at value -22.41, with -21.07 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -449.62. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -16.13.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 429.75. The receivables turnover for the company is 3.28for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.54.
Conclusion
To put it simply, ARS Pharmaceuticals Inc (SPRY) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
